Pharvaris (NASDAQ:PHVS) Shares Acquired by Octagon Capital Advisors LP

Octagon Capital Advisors LP raised its holdings in Pharvaris (NASDAQ:PHVS - Free Report) by 25.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,000 shares of the company's stock after buying an additional 157,530 shares during the period. Pharvaris comprises about 2.5% of Octagon Capital Advisors LP's holdings, making the stock its 16th largest position. Octagon Capital Advisors LP owned 1.49% of Pharvaris worth $14,914,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Pharvaris in the fourth quarter valued at approximately $64,000. Barclays PLC acquired a new stake in shares of Pharvaris during the 3rd quarter worth $106,000. KLP Kapitalforvaltning AS acquired a new position in shares of Pharvaris in the 4th quarter valued at about $111,000. Finally, Legal & General Group Plc grew its stake in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after buying an additional 994 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on PHVS shares. Cantor Fitzgerald assumed coverage on Pharvaris in a report on Tuesday, April 29th. They issued an "overweight" rating and a $28.00 price target for the company. JMP Securities upped their price objective on Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research note on Friday, January 31st.

Pharvaris Stock Down 1.1%

PHVS stock opened at $16.81 on Tuesday. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50. The company has a 50 day moving average of $15.31 and a two-hundred day moving average of $17.80. The company has a market cap of $878.99 million, a price-to-earnings ratio of -6.00 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.06. On average, research analysts anticipate that Pharvaris will post -2.71 EPS for the current year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.